A limitation to FISH testing was proposed only for GCB and double-protein expressor (DPE) (i.e., cases with MYC and BCL2 protein overexpression) DLBCL cases, thus reducing the analyses to 15% of patients [84], but until now studies on large cohorts of patients are lacking. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.